(Q35074214)

6 August 2017

1 reference

title

Treatment of obesity: an update on anti-obesity medications (English)

1 reference

6 August 2017

0 references

Halpern A

1

1 reference

6 August 2017

Mancini MC

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

25-42

1 reference

Obesity in Britain: gluttony or sloth?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Current and potential drugs for treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Biological actions of drugs affecting serotonin and eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

The mechanism of amphetamine-induced loss of weight; a consideration of the theory of hunger and appetite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Metabolism and disposition of N-(2-cyanoethyl)amphetamine (fenproporex) and amphetamine: study in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sumatriptan decreases food intake and increases plasma growth hormone in healthy women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Long-term use of diethylpropion in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Further cases of valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00083.X

10.1046/J.1467-789X.2003.00083.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference